OBJECTIVE: COVID-19 toes represent the main dermatological COVID-19 cutaneous manifestation in pediatric patients. Its diagnosis exposes the whole family to social stigma and this aspect was not previously evaluated.PATIENTS AND METHODS: This was a multicenter, case-control, observational study that compared the family impact of COVID-19 toes vs. psoriasis (PsO). We enrolled 46 pediatric patients (23 with psoriasis and 23 with COVID-19 toes, age and gender matched) and their parents/caregivers that had to fill the Dermatitis Family Impact (DFI) questionnaire.RESULTS: DFI index did not differ significantly between both subgroups (p= 0.48), and in psoriatic patients did not correlate with both Psoriasis Area Severity Index (PASI) (p= 0.59) and itchVAS (p= 0.16).CONCLUSIONS: COVID-19 toes, a transitory dermatosis, exerted a similar impact/ perturbation on family dynamics than PsO, a well-known stigmatizing, chronic inflammatory dermatosis.

Chilblain-like lesions (COVID-19 toes) have the same impact on family members than psoriasis systemically treated: insights from a case-control study targeting the pediatric population

Savoia, P;
2022-01-01

Abstract

OBJECTIVE: COVID-19 toes represent the main dermatological COVID-19 cutaneous manifestation in pediatric patients. Its diagnosis exposes the whole family to social stigma and this aspect was not previously evaluated.PATIENTS AND METHODS: This was a multicenter, case-control, observational study that compared the family impact of COVID-19 toes vs. psoriasis (PsO). We enrolled 46 pediatric patients (23 with psoriasis and 23 with COVID-19 toes, age and gender matched) and their parents/caregivers that had to fill the Dermatitis Family Impact (DFI) questionnaire.RESULTS: DFI index did not differ significantly between both subgroups (p= 0.48), and in psoriatic patients did not correlate with both Psoriasis Area Severity Index (PASI) (p= 0.59) and itchVAS (p= 0.16).CONCLUSIONS: COVID-19 toes, a transitory dermatosis, exerted a similar impact/ perturbation on family dynamics than PsO, a well-known stigmatizing, chronic inflammatory dermatosis.
File in questo prodotto:
File Dimensione Formato  
Eur Rev Med Pharmacol Sci 2022.pdf

file ad accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Dominio pubblico
Dimensione 611.7 kB
Formato Adobe PDF
611.7 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11579/161982
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact